Immunogenicity and Safety of Hepatitis B Vaccine With a Toll-like Receptor 9 Agonist Adjuvant (HEPLISAV-B) in HBV Vaccine-naive People With Human Immunodeficiency Virus (HIV)

Serological response with Heplisav-B® in prior Hepatitis B vaccine non-responders living with HIV

(2021) Rebecca Khaimova et al.   VACCINE

Immune Response to Hepatitis B Virus Vaccine Among People Living With HIV: A Meta-Analysis

(2021) Yakun Tian et al.   Frontiers in Immunology

Brief Report: Heplisav-B Seroprotection in People With HIV: A Single-Center Experience

(2020) Samuel R. Schnittman et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

(2018) Sam Jackson et al.   VACCINE

Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease

(2013) Robert S. Janssen et al.   VACCINE

Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age

(2013) William L. Heyward et al.   VACCINE

Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age

(2012) Scott A. Halperin et al.   VACCINE

Long-term response rates of successful hepatitis B vaccination in HIV-infected patients

(2012) Vania Baptista Lopes et al.   VACCINE

Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220

(2010) E.T. Overton et al.   VACCINE